{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:32:52Z","timestamp":1786739572512,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The primary purpose was to compare the effect of 2 mg and 4 mg of intravenous zoledronic acid (ZA) on change in the lumbar spine (LS) bone mineral density (BMD) at the end of 1 year in postmenopausal women with osteoporosis. The secondary objectives were changes in BMD at the total hip and femoral neck, change in bone turnover markers (BTMs), and the incidence of new fractures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a double-blind, parallel-arm, randomized control trial with an allocation ratio of 1:1 done in 70 postmenopausal women with osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>\n                      The mean (\u00b1standard deviation) percentage increase in LS BMD at the end of 1 year was 4.86% \u00b1 3.05% and 5.35% \u00b1 3.73% in the 2 mg and 4 mg group, respectively. The dose of 2 mg ZA proved to be inferior to 4 mg with a noninferiority margin of 0.5%. There was no difference in BMD change at hip and BTMs between the two groups at the end of 1 year. Only one patient in 4 mg group developed two new vertebral fractures during a 12-month follow-up. Acute-phase reactions were the most common (43%) side-effects noted without any difference between the two groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.63).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study failed to show the noninferiority of 2 mg ZA compared to 4 mg ZA for change in LS BMD at the end of 1 year.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrpp.jrpp_20_130","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T11:44:33Z","timestamp":1627904673000},"page":"71-77","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effect of 2 mg Versus 4 mg of Intravenous Zoledronic Acid on Bone Mineral Density at the Lumbar Spine in Indian Postmenopausal Women with Osteoporosis"],"prefix":"10.4103","volume":"10","author":[{"given":"Harsh","family":"Durgia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadishkumar","family":"Kamalanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govindarajalou","family":"Ramkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagili Vihaya Bhaskar","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayaprakash","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Palui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henith","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20240907","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s001980050281","article-title":"An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation","volume":"11","author":"Kanis","year":"2000","journal-title":"Osteoporos Int"},{"key":"R2-3-20240907","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11657-014-0182-3","article-title":"Estimating prevalence of osteoporosis: Examples from industrialized countries","volume":"9","author":"Wade","year":"2014","journal-title":"Arch Osteoporos"},{"key":"R3-3-20240907","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4103\/2230-8210.137485","article-title":"The asia-pacific regional audit-epidemiology, costs, and burden of osteoporosis in India 2013: A report of International Osteoporosis Foundation","volume":"18","author":"Mithal","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"R4-3-20240907","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: An endocrine society clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-3-20240907","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s00198-010-1507-8","article-title":"Bone health in healthy Indian population aged 50 years and above","volume":"22","author":"Marwaha","year":"2011","journal-title":"Osteoporos Int"},{"key":"R6-3-20240907","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"R7-3-20240907","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"R8-3-20240907","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1210\/jc.2011-2081","article-title":"Low-dose zoledronate in osteopenic postmenopausal women: A randomized controlled trial","volume":"97","author":"Grey","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-3-20240907","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"R10-3-20240907","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"R11-3-20240907","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00198-017-4082-4","article-title":"National Bone Health Alliance Bone Turnover Marker Project. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability","volume":"28","author":"Szulc","year":"2017","journal-title":"Osteoporos Int"},{"key":"R12-3-20240907","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"R13-3-20240907","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jocd.2016.03.003","article-title":"Best practices for dual-energy X-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry Guidance","volume":"19","author":"Lewiecki","year":"2016","journal-title":"J Clin Densitom"},{"key":"R14-3-20240907","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2008-2765","article-title":"Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density","volume":"94","author":"Eastell","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-3-20240907","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/ar125","article-title":"Bone loss. Epidemiology of bone loss","volume":"2","author":"Hunter","year":"2000","journal-title":"Arthritis Res"},{"key":"R16-3-20240907","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/bonekey.2014.24","article-title":"Bisphosphonates and bone quality","volume":"3","author":"Pazianas","year":"2014","journal-title":"Bonekey Rep"},{"key":"R17-3-20240907","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","article-title":"Characterization of and risk factors for the acute-phase response after zoledronic acid","volume":"95","author":"Reid","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R18-3-20240907","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00774-019-01050-8","article-title":"Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: Randomized, open-label, Japanese OZ study","volume":"38","author":"Okimoto","year":"2020","journal-title":"J Bone Miner Metab"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.JRPP_20_130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:30:08Z","timestamp":1786735808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.JRPP_20_130"}},"subtitle":["A Double-blind Parallel-arm Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jrpp.jrpp_20_130","relation":{},"ISSN":["2319-9644"],"issn-type":[{"value":"2319-9644","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}